oral TRPA1 ion-channel inhibitor

for asthma, target engagement in HV Ph. I

from ligand-based design, cryo-EM structure

J. Exp. Med., Apr. 5, 2021

Genentech Inc., South San Francisco, CA

The Genentech TRPA1 ion-channel inhibitor, GDC-0334, is an oral candidate for asthma that demonstrated target engagement in a non-invasive skin- based Ph. I study. It reduces TRPA1 agonist-induced symptoms in…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.